Monopar Therapeutics Files 8-K
Ticker: MNPR · Form: 8-K · Filed: May 7, 2025 · CIK: 1645469
| Field | Detail |
|---|---|
| Company | Monopar Therapeutics (MNPR) |
| Form Type | 8-K |
| Filed Date | May 7, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure
TL;DR
Monopar Therapeutics filed an 8-K, signaling a material event. Details pending.
AI Summary
Monopar Therapeutics Inc. filed an 8-K on May 7, 2025, reporting an event that occurred on the same date. The filing is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. No specific details regarding the nature of the event or any financial transactions were provided in the excerpt.
Why It Matters
This filing indicates a material event has occurred for Monopar Therapeutics, requiring public disclosure. Investors should look for subsequent filings or press releases for details.
Risk Assessment
Risk Level: low — The filing itself is a standard procedural disclosure and does not contain information that inherently increases risk.
Key Players & Entities
- Monopar Therapeutics Inc. (company) — Registrant
- May 7, 2025 (date) — Date of earliest event reported
- 1000 Skokie Blvd. , Suite 350 , Wilmette , IL 60091 (address) — Principal executive offices
- 847-388-0349 (phone_number) — Registrant's telephone number
FAQ
What specific event triggered this 8-K filing for Monopar Therapeutics?
The provided excerpt does not specify the exact event that triggered the 8-K filing; it only states the date of the earliest event reported as May 7, 2025.
When was this 8-K filed with the SEC?
This 8-K was filed on May 7, 2025.
What is the principal business address of Monopar Therapeutics?
The principal executive offices of Monopar Therapeutics are located at 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091.
What is the trading symbol for Monopar Therapeutics?
The excerpt mentions 'Trading Symbol(s)' but does not list the specific symbol for Monopar Therapeutics.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 7, 2025 regarding Monopar Therapeutics (MNPR).